HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G ‘Clear-Eyed’ On Challenges Ahead; Growth Will Soften, But Strategic Priorities Go Unchanged

Executive Summary

Environmental sustainability and DEI will remain key priorities for P&G as it enters a fiscal 2023 that augurs even greater volatility than 2022. The firm’s net sales for the 12 months ended 30 June increased 5%, or 7% organic, to $80.2bn, propelled by an 8% pricing increase in the fourth quarter.

You may also be interested in...



P&G Looks To Change Children’s Toothpaste Market With Crest Kids Color Changing

Color of the toothpaste, which P&G North America oral care chief says is “only one of its kind on the market today,” changes from blue to pink after two minutes of brushing.

P&G's Organic Growth Despite Market Volatility: Validation For Firm, Surprise For Analysts

P&G reported 7% organic and 1% net sales growth in latest quarter to $20.6bn. Analysts projected organic growth of 5.5% and saw results as indicator firm’s execution strategy, which includes cutting back on costs, is working.

US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?

Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel